Cargando…
Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah
BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among h...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Faisal Specialist Hospital and Research Centre
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357293/ https://www.ncbi.nlm.nih.gov/pubmed/35933611 http://dx.doi.org/10.5144/0256-4947.2022.229 |
_version_ | 1784763678730485760 |
---|---|
author | Housawi, Abdulrahman A. Qazi, Shazada Junaid S. Jan, Abdulhalem A. Osman, Rashid A. Alshamrani, Mashil M. AlFaadhel, Talal A. AlHejaili, Fayez F. Al-Tawfiq, Jaffar A. Wafa, Ahmed A. Hamza, Abdulmageed E. Hassan, Moustafa A. Alharbi, Suliman A. Albasheer, Hamza Almohmmdi, Majed M. Alsisi, Salem A. Mankowski, Michal Van de Klundert, Joris Alhelal, Amal M. Sala, Fatima H. Kheyami, Ali Alhomayeed, Bader A. |
author_facet | Housawi, Abdulrahman A. Qazi, Shazada Junaid S. Jan, Abdulhalem A. Osman, Rashid A. Alshamrani, Mashil M. AlFaadhel, Talal A. AlHejaili, Fayez F. Al-Tawfiq, Jaffar A. Wafa, Ahmed A. Hamza, Abdulmageed E. Hassan, Moustafa A. Alharbi, Suliman A. Albasheer, Hamza Almohmmdi, Majed M. Alsisi, Salem A. Mankowski, Michal Van de Klundert, Joris Alhelal, Amal M. Sala, Fatima H. Kheyami, Ali Alhomayeed, Bader A. |
author_sort | Housawi, Abdulrahman A. |
collection | PubMed |
description | BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. DESIGN: Cross-sectional study with a prospective follow-up period. SETTING: Hemodialysis centers in Madinah region. PATIENTS AND METHODS: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOME MEASURES: SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. RESULTS: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity. CONCLUSION: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others. LIMITATIONS: Unable to collect four samples for each participant; limited to one urban center. CONFLICT OF INTEREST: None. |
format | Online Article Text |
id | pubmed-9357293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | King Faisal Specialist Hospital and Research Centre |
record_format | MEDLINE/PubMed |
spelling | pubmed-93572932022-08-30 Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah Housawi, Abdulrahman A. Qazi, Shazada Junaid S. Jan, Abdulhalem A. Osman, Rashid A. Alshamrani, Mashil M. AlFaadhel, Talal A. AlHejaili, Fayez F. Al-Tawfiq, Jaffar A. Wafa, Ahmed A. Hamza, Abdulmageed E. Hassan, Moustafa A. Alharbi, Suliman A. Albasheer, Hamza Almohmmdi, Majed M. Alsisi, Salem A. Mankowski, Michal Van de Klundert, Joris Alhelal, Amal M. Sala, Fatima H. Kheyami, Ali Alhomayeed, Bader A. Ann Saudi Med Original Article BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. DESIGN: Cross-sectional study with a prospective follow-up period. SETTING: Hemodialysis centers in Madinah region. PATIENTS AND METHODS: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOME MEASURES: SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. RESULTS: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity. CONCLUSION: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others. LIMITATIONS: Unable to collect four samples for each participant; limited to one urban center. CONFLICT OF INTEREST: None. King Faisal Specialist Hospital and Research Centre 2022-07 2022-08-04 /pmc/articles/PMC9357293/ /pubmed/35933611 http://dx.doi.org/10.5144/0256-4947.2022.229 Text en Copyright © 2022, Annals of Saudi Medicine, Saudi Arabia https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). The details of which can be accessed at http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Article Housawi, Abdulrahman A. Qazi, Shazada Junaid S. Jan, Abdulhalem A. Osman, Rashid A. Alshamrani, Mashil M. AlFaadhel, Talal A. AlHejaili, Fayez F. Al-Tawfiq, Jaffar A. Wafa, Ahmed A. Hamza, Abdulmageed E. Hassan, Moustafa A. Alharbi, Suliman A. Albasheer, Hamza Almohmmdi, Majed M. Alsisi, Salem A. Mankowski, Michal Van de Klundert, Joris Alhelal, Amal M. Sala, Fatima H. Kheyami, Ali Alhomayeed, Bader A. Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah |
title | Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah |
title_full | Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah |
title_fullStr | Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah |
title_full_unstemmed | Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah |
title_short | Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah |
title_sort | prevalence of anti-sars-cov-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from madinah |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357293/ https://www.ncbi.nlm.nih.gov/pubmed/35933611 http://dx.doi.org/10.5144/0256-4947.2022.229 |
work_keys_str_mv | AT housawiabdulrahmana prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT qazishazadajunaids prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT janabdulhalema prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT osmanrashida prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT alshamranimashilm prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT alfaadheltalala prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT alhejailifayezf prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT altawfiqjaffara prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT wafaahmeda prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT hamzaabdulmageede prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT hassanmoustafaa prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT alharbisulimana prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT albasheerhamza prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT almohmmdimajedm prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT alsisisalema prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT mankowskimichal prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT vandeklundertjoris prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT alhelalamalm prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT salafatimah prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT kheyamiali prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah AT alhomayeedbadera prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah |